Xponance Inc. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the second quarter, Holdings Channel.com reports. The institutional investor bought 10,214 shares of the company’s stock, valued at approximately $65,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Profund Advisors LLC increased its position in Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after buying an additional 1,680 shares in the last quarter. ProShare Advisors LLC increased its holdings in Amneal Pharmaceuticals by 8.6% during the 1st quarter. ProShare Advisors LLC now owns 21,902 shares of the company’s stock worth $133,000 after purchasing an additional 1,726 shares in the last quarter. SG Americas Securities LLC increased its holdings in Amneal Pharmaceuticals by 18.8% during the 1st quarter. SG Americas Securities LLC now owns 20,112 shares of the company’s stock worth $122,000 after purchasing an additional 3,177 shares in the last quarter. Rothschild Investment LLC bought a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $26,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Amneal Pharmaceuticals by 13.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock worth $222,000 after purchasing an additional 4,115 shares in the last quarter. 31.82% of the stock is owned by institutional investors.
Amneal Pharmaceuticals Stock Performance
AMRX stock opened at $8.55 on Friday. The firm has a market cap of $2.64 billion, a PE ratio of -15.27 and a beta of 1.18. The company has a quick ratio of 0.82, a current ratio of 1.33 and a debt-to-equity ratio of 121.31. The business has a 50 day moving average of $8.14 and a 200-day moving average of $7.05. Amneal Pharmaceuticals, Inc. has a 12-month low of $3.36 and a 12-month high of $8.94.
Analyst Upgrades and Downgrades
AMRX has been the subject of a number of recent research reports. Barclays boosted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Truist Financial upped their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $9.40.
Check Out Our Latest Stock Report on AMRX
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Featured Stories
- Five stocks we like better than Amneal Pharmaceuticals
- How to Use the MarketBeat Excel Dividend Calculator
- When Is the Best Time to Invest in Mutual Funds?
- How to Choose Top Rated Stocks
- Is NVIDIA Stock in a Correction or Consolidation?
- What Are Dividend Challengers?
- 3 Oversold Stocks with Big RSI Rebound Potential
Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report).
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.